Commissioning and clinical implementation of the first commercial independent Monte Carlo 3D dose calculation to replace CyberKnife M6™ patient-specific QA measurements.


Journal

Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176

Informations de publication

Date de publication:
Nov 2020
Historique:
received: 21 03 2020
revised: 21 03 2020
accepted: 31 07 2020
pubmed: 27 10 2020
medline: 22 6 2021
entrez: 26 10 2020
Statut: ppublish

Résumé

To report on the commissioning and clinical validation of the first commercially available independent Monte Carlo (MC) three-dimensional (3D) dose calculation for CyberKnife robotic radiosurgery system® (Accuray, Sunnyvale, CA). The independent dose calculation (IDC) by SciMoCa® (Scientific RT, Munich, Germany) was validated based on water measurements of output factors and dose profiles (unshielded diode, field-size dependent corrections). A set of 84 patient-specific quality assurance (QA) measurements for multi-leaf collimator (MLC) plans, using an Octavius two-dimensional SRS1000 array (PTW, Freiburg, Germany), was compared to results of respective calculations. Statistical process control (SPC) was used to detect plans outside action levels. Of all output factors for the three collimator systems of the CyberKnife, 99% agreed within 2% and 81% within 1%, with a maximum deviation of 3.2% for a 5-mm fixed cone. The profiles were compared using a one-dimensional gamma evaluation with 2% dose difference and 0.5 mm distance-to-agreement (Γ(2,0.5)). The off-centre ratios showed an average pass rate >99% (92-100%). The agreement of the depth dose profiles depended on field size, with lowest pass rates for the smallest MLC field sizes. The average depth dose pass rate was 88% (35-99%). The IDCs showed a Γ(2,1) pass rate of 98%. Statistical process control detected six plans outside tolerance levels in the measurements, all of which could be attributed the measurement setup. Independent dose calculations showed problems in five plans, all due to differences in the algorithm between TPS and IDC. Based on these results changes were made in the class solution for treatment plans. The first commercially available MC 3D dose IDC was successfully commissioned and validated for the CyberKnife and replaced all routine patient-specific QA measurements in our clinic.

Identifiants

pubmed: 33103343
doi: 10.1002/acm2.13046
pmc: PMC7700940
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

304-311

Informations de copyright

© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.

Références

J Appl Clin Med Phys. 2002 Spring;3(2):63-72
pubmed: 11958647
Med Phys. 2018 Jun 16;:
pubmed: 29908062
Phys Med Biol. 2014 Mar 21;59(6):N11-7
pubmed: 24594929
Phys Med. 2016 Oct;32(10):1225-1237
pubmed: 27659008
J Appl Clin Med Phys. 2015 Jul 08;16(4):290–305
pubmed: 26219013
Radiat Oncol. 2019 Sep 18;14(1):172
pubmed: 31533746
Med Phys. 2011 Feb;38(2):1037-44
pubmed: 21452741
Med Phys. 2013 Jul;40(7):070601
pubmed: 23822401
Phys Med Biol. 2017 Dec 19;63(1):015015
pubmed: 29256450
Med Phys. 2016 May;43(5):2063
pubmed: 27147318
Phys Med Biol. 2017 Feb 7;62(3):1076-1095
pubmed: 28033110
Radiother Oncol. 2008 Dec;89(3):330-7
pubmed: 18701175
J Appl Clin Med Phys. 2015 Sep 08;16(5):14–34
pubmed: 26699330
Med Phys. 2006 Aug;33(8):2955-63
pubmed: 16964874
Phys Med. 2016 Jun;32(6):838-46
pubmed: 27245301
Med Phys. 2007 Jun;34(6):1967-74
pubmed: 17654899
Med Phys. 2011 Jan;38(1):504-30
pubmed: 21361219
Med Phys. 2011 Oct;38(10):5477-89
pubmed: 21992366
Phys Med Biol. 2000 Sep;45(9):2483-95
pubmed: 11008950
Med Phys. 2008 Oct;35(10):4417-25
pubmed: 18975688
Med Phys. 2018 May;45(5):1811-1821
pubmed: 29532493
Phys Med. 2017 Oct;42:319-326
pubmed: 28662849
Med Phys. 2018 Apr;45(4):e53-e83
pubmed: 29443390
Phys Med. 2017 Jul;39:50-58
pubmed: 28711188
J Appl Clin Med Phys. 2009 Feb 05;10(1):120-128
pubmed: 19223841
Med Phys. 2004 Jun;31(6):1593-602
pubmed: 15259664
Med Phys. 2005 Sep;32(9):2777-86
pubmed: 16266091
Radiother Oncol. 2012 Mar;102(3):364-70
pubmed: 22239866
Phys Med. 2015 Jul;31(5):476-83
pubmed: 26003217
Med Phys. 2011 Jun;38(6):2914-36
pubmed: 21815366

Auteurs

Maaike T W Milder (MTW)

Department of Radiotherapy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.

Markus Alber (M)

Section for Medical Physics, Department of Radiation Oncology, University Clinic Heidelberg, Heidelberg, Germany.
Scientific RT GmbH, Munich, Germany.

Matthias Söhn (M)

Scientific RT GmbH, Munich, Germany.

Mischa S Hoogeman (MS)

Department of Radiotherapy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH